Articles from Kincell Bio

Kincell Bio, a leading U.S. cell therapy contract development and manufacturing organization (CDMO), today announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T cells (Tregs). Under the partnership, Kincell Bio will provide comprehensive CMC development and GMP manufacturing support to accelerate RegCell’s lead Treg program toward clinical trial evaluation.

Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, today announced the promotion of three accomplished executives to strengthen its leadership team and advance its mission of delivering life-changing therapies to patients worldwide.

Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, is pleased to announce the promotion of Lawrence “Larry” Pitcher to Chief Executive Officer, effective immediately. Pitcher succeeds Mark R. Bamforth OBE, who guided the company through a successful phase of growth as CEO and will continue to support the transition in a strategic capacity as Executive Chair of the Board.

Kincell Bio, a leading US cell therapy CDMO, is excited to announce a partnership with Moonlight Bio, Inc., a Seattle-based biotech company pioneering advanced T cell therapies for solid tumors. In this partnership, Kincell provides CMC development and GMP manufacturing services to advance Moonlight’s lead T cell therapy program into clinic trials.

Kincell Bio announced the completion of a $22 million round, led by a new investor, NewSpring Capital through its dedicated healthcare strategy, NewSpring Healthcare, which invests in innovative companies in the lower-middle market that improve the delivery of healthcare or bend the cost curve through technology and human capital efficiencies. The round was also led by existing investor, Kineticos Life Sciences, an operationally focused private equity firm specializing in private investments across pharma services tools and equipment, and other existing investors.

Kincell Bio, a leader in cell therapy development and manufacturing, is excited to announce the appointment of Larry Pitcher as Chief Operating Officer (COO). Larry brings extensive experience in the advanced therapies Contract Development and Manufacturing Organization (CDMO) space, having had P&L responsibility, deep operational experience including facility expansions and key leadership roles.

Kincell Bio, a leader in cell therapy development and manufacturing, is excited to announce the appointment of Mark R. Bamforth as Chief Executive Officer (CEO), effective immediately. Mark, who has served as Chair of the Board since May 2024, brings decades of industry experience to the role and will play a pivotal part in advancing Kincell Bio’s mission to support innovators in the rapidly growing cell therapy sector.

Kincell Bio, a leader in cell therapy development and manufacturing, is excited to announce the appointment of Stewart McNaull, PhD, as Chief Commercial Officer (CCO). With extensive experience in the advance therapies Contract Development and Manufacturing Organization (CDMO) space and a robust technical background, Stewart will play a pivotal role in steering Kincell Bio’s growth trajectory and enhancing our commitment to serving cell therapy innovators and the patients who ultimately benefit from these groundbreaking therapies.

Kincell Bio, a cell therapy-focused cGMP contract development and manufacturing organization (CDMO), today announced that it has welcomed a new client for the production of a cell therapy product to address degenerative disease.

Kincell Bio, a technology-forward cell therapy cGMP contract development and manufacturing organization (CDMO), today announced that it has welcomed a new partner for the production of early-phase clinical material of an allogeneic cell therapy product. This contract follows the acquisition of the GMP-ready facility in April 2024 and augments the manufacturing activities already occurring at the site. The agreement represents a multi-year relationship and strongly validates the team’s competency in allogeneic cell therapy production and release.

Serial entrepreneur has created, built and sold three CDMOs

SYDNEY, Australia and GAINESVILLE, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Imugene, Ltd. (“Imugene”)(ASX: IMU) and Kincell Bio, LLC (“Kincell”), announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice (CGMP) manufacturing facility and the transfer of process and analytical development activities to Kincell.

Cell therapy CDMO spins out of Inceptor Bio to help innovators develop and manufacture life-saving cell therapies